

**REMARKS**

Claims 1, 3-7, 9, 10, 12, 13, 18 and 19 are pending.

The amendment to claim 7 is purely cosmetic.

Claim 9 has been amended to remove multiple dependency. Claim 9 has been made to depend on only claim 7, not on claim 8 in the alternative. Applicants submit that the scope of the amended claim recitation in claim 9 has not been narrowed because claim 7 is broader than claim 8 (claim 8 merely recited a property of the composition according to claim 7).

Similarly, the amendment to claim 12 removes multiple dependency, so that claim 12 now depends on only claim 10, not on claim 11 in the alternative. The scope of the amended claim recitation in claim 12 has not been narrowed because claim 10 is broader than claim 11 (claim 11 merely recited a property of the composition according to claim 10).

**Sequence Listing**

The PTO wanted more information on the second amino acid residue in the 7<sup>th</sup> sequence in the Sequence Listing filed on October 6, 2003. A Substitute Sequence Listing was filed on January 14, 2004 providing more information on the second amino acid in the 7<sup>th</sup> sequence. Copies of the Substitute Sequence Listing, in paper and computer readable form, are resubmitted herein.

Withdrawal of the objection related to the sequence listing is requested.

Claim Rejection under 35 U.S.C. 112, First Paragraph

Claims 7-12 were rejected as not enabled for the full scopes of the claims. Applicants respectfully traverse the rejection.

Claims 8 and 11 have been cancelled. The specification presents experimental data on the effectiveness of the composition of the invention in inhibiting cancer cells. Applicants submit that, with the application's disclosure, a person skilled in the art would know how to make and use the composition of the invention in treating cancer.

Withdrawal of the rejection is requested

Allowed Claims


Applicants thank the Examiner for allowing claims 1, 3-6, 13, 18 and 19.

Conclusion

In view of the above reasoning, applicants submit that the application is in a condition for allowance. A Notice of Allowance is believed in order.

In the event that the filing of this paper is not deemed timely, Applicants petition for an appropriate extension of time. Any petition fee for the extension of time and any other fees that may be required in relation to this paper can be charged to Deposit Account No. 01-2300, referencing Docket No. 026390-00001.

Respectfully submitted,

  
\_\_\_\_\_  
King L. Wong  
Registration No. 37,500

Customer No. 004372  
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC  
1050 Connecticut Avenue, N.W.,  
Suite 400  
Washington, D.C. 20036-5339  
Tel: (202) 857-6000  
Fax: (202) 638-4810

Enclosure: Petition for Extension of Time

KLW:elp

240352\_1.DOC